Valuation: Iqvia Holdings

Market Cap 42.77B 36.63B 34.28B 31.38B 58.89B 4,092B 59.66B 405B 158B 2,056B 161B 157B 6,799B P/E 2026 *
33.5x
P/E 2027 * 26.7x
Enterprise Value 56.6B 48.48B 45.36B 41.52B 77.93B 5,415B 78.96B 536B 209B 2,720B 213B 208B 8,997B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 3.02x
Free-Float
62.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 03/10/2016
Director of Finance/CFO 51 28/02/2026
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 68 05/02/2015
Chairman 64 03/10/2016
Director/Board Member 69 03/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+2.60% - - 42.77B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.51%+4.43%+83.10%+126.32% 30.72B
Weighted average by Cap. +0.56%+4.72%+99.57%+146.30%

Financials

2026 *2027 *
Net sales 17.41B 14.92B 13.96B 12.78B 23.98B 1,666B 24.29B 165B 64.31B 837B 65.39B 63.97B 2,768B 18.47B 15.82B 14.8B 13.55B 25.43B 1,767B 25.77B 175B 68.2B 888B 69.35B 67.84B 2,936B
Net income 1.28B 1.09B 1.02B 936M 1.76B 122B 1.78B 12.09B 4.71B 61.35B 4.79B 4.69B 203B 1.58B 1.35B 1.27B 1.16B 2.18B 151B 2.2B 14.96B 5.84B 75.95B 5.93B 5.8B 251B
Net Debt 13.83B 11.85B 11.08B 10.15B 19.04B 1,323B 19.29B 131B 51.07B 665B 51.93B 50.8B 2,198B 13.05B 11.17B 10.46B 9.57B 17.96B 1,248B 18.2B 124B 48.17B 627B 48.98B 47.92B 2,074B
Logo Iqvia Holdings
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (40.6%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.9%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.5%), Europe and Africa (31.8%) and Asia/Pacific (20.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-